ERBB2 and metastatic neoplasm: Of these, 91 were excluded: 22 (4.0%) had primary metastatic disease; 5 (1.0%) received adjuvant HER2-targeted therapy within a clinical trial; 17 (3.0%) had current CVD; and 47 (9.0%) had unknown oncological treatment since the medical records (at that time, paper archives) could not be retrieved, leaving a total of 433 women that comprised the study population.